July 17, 2009
A Lancet comment examines combination antiretroviral therapy (cART) in low-income and middle-income countries. According to the authors, "the presence of patients in whom therapy fails in access programmes provides a unique opportunity to design nested prospective randomised studies that aim to find solutions systematically and rigorously." They conclude, "We believe that it is time to reject a compromise approach to access to HIV therapy in low-income and middle-income countries, and to re-emphasise the Sydney Declaration and its call for dedicated funding for research" (Boyd et al. 7/18).
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily Global Health Policy Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.